Cellectis appoints Loan Hoang-Sayag as Chief Medical Officer
Biopharmaceutical firm Cellectis has named Dr. Loan Hoang-Sayag as its new Chief Medical Officer to oversee clinical development of its gene-edited CAR T-cell therapies.
Cellectis has appointed Dr. Loan Hoang-Sayag to the role of Chief Medical Officer, effective immediately. She will be responsible for guiding the company’s product candidates into clinical-stage development and overseeing all therapeutic strategy and operational management.
Dr. Hoang-Sayag transitions to Cellectis from Quintiles Transnational, where she served as Senior Director of Medical Science. Her background in oncology clinical research and global drug development is expected to support the company’s efforts in advancing its portfolio of allogeneic chimeric antigen receptor (CAR) T-cell therapies.
CEO Dr. André Choulika stated that the appointment is intended to strengthen the company’s clinical strategy and management of its therapeutic activities. Cellectis continues to focus on its proprietary gene-editing platform and the transition of its immunotherapy candidates toward clinical validation.